- Home
- SNCY vs CMPX Comparison
SNCY vs CMPX Comparison
Compare SNCY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- CMPX
- Stock Information
- Founded
- SNCY 1982
- CMPX 2014
- Country
- SNCY United States
- CMPX United States
- Employees
- SNCY N/A
- CMPX N/A
- Industry
- SNCY Air Freight/Delivery Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- CMPX Health Care
- Exchange
- SNCY Nasdaq
- CMPX Nasdaq
- Market Cap
- SNCY 634.5M
- CMPX 576.5M
- IPO Year
- SNCY 2021
- CMPX N/A
- Fundamental
- Price
- SNCY $11.31
- CMPX $4.04
- Analyst Decision
- SNCY Buy
- CMPX Strong Buy
- Analyst Count
- SNCY 6
- CMPX 7
- Target Price
- SNCY $18.50
- CMPX $14.71
- AVG Volume (30 Days)
- SNCY 1.1M
- CMPX 1.8M
- Earning Date
- SNCY 10-29-2025
- CMPX 11-11-2025
- Dividend Yield
- SNCY N/A
- CMPX N/A
- EPS Growth
- SNCY 20.75
- CMPX N/A
- EPS
- SNCY 1.07
- CMPX N/A
- Revenue
- SNCY $1,100,145,000.00
- CMPX N/A
- Revenue This Year
- SNCY $5.97
- CMPX N/A
- Revenue Next Year
- SNCY $10.61
- CMPX N/A
- P/E Ratio
- SNCY $10.73
- CMPX N/A
- Revenue Growth
- SNCY 3.76
- CMPX N/A
- 52 Week Low
- SNCY $8.10
- CMPX $1.27
- 52 Week High
- SNCY $18.59
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- SNCY 40.29
- CMPX 64.24
- Support Level
- SNCY $11.18
- CMPX $3.31
- Resistance Level
- SNCY $12.11
- CMPX $3.80
- Average True Range (ATR)
- SNCY 0.46
- CMPX 0.23
- MACD
- SNCY -0.11
- CMPX 0.02
- Stochastic Oscillator
- SNCY 13.68
- CMPX 96.03
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.